




RealRate

MEDICINAL PRODUCTS 2017

Navidea Biopharmaceuticals Inc.
Rank 37 of 44



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable General and Administrative Expense, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is -155%, being 108% points below the market average of -47%.

Input Variable	Value in 1000 USD
Assets, Current	10,826
Assets, Non-Current	203
General and Administrative Expense	0
Goodwill	181
Liabilities, Current	69,862
Liabilities, Non-Current	599
Other Assets	0
Other Compr. Net Income	0
Other Expenses	24,193
Other Liabilities	9,667
Other Net Income	-12,086
Other Revenues	21,970
Property, Plant and Equipment, Net	1,252
Research and Development	0

Output Variable	Value in 1000 USD
Liabilities	80,128
Assets	12,462
Expenses	24,193
Revenues	21,970
Stockholders Equity	-67,666
Net Income	-14,309
Comprehensive Net Income	-14,309
Economic Capital Ratio	-155%